Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Q4 Revenues, Profit Beat Analysts' Expectations

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today reported soaring profits and a 57 percent increase in revenues for the fourth quarter of 2007 ended Dec. 31, beating Wall Street’s expectations for the firm.
 
Thermo Fisher reported fourth-quarter revenues of $2.62 billion compared to $1.67 billion in the fourth quarter of 2006. Analysts surveyed by Thomson Financial, on average, expected revenues of $2.51 billion. On a pro forma basis — if the operations of Thermo Electron and Fisher Scientific had been combined for the full fourth quarter of 2006 — revenue growth would have been 12 percent from $2.35 billion last year.
 
The firms completed their $10.6 billion merger in November 2006.
 
Sales for its Analytical Technologies segment increased 14 percent on a pro forma basis to $1.17 billion from $1.02 billion year over year. Revenues for the Laboratory Products and Services Segment grew 10 percent on a pro forma basis to $1.55 billion from $1.4 billion.
 
Thermo Fisher posted a fourth-quarter profit of $239.8 million, or $.54 per share, up from a profit of $25.3 million, or $.08 per share, in the comparable period last year, when the firm took a $125 million charge related to the merger. On a pro forma basis, net earnings were $.76 per share, up from $.57 in the fourth quarter of 2006. The results beat analysts’ expectations of $.69 per share.
 
The firm’s R&D costs grew 17.6 percent in the quarter to $61.4 million from $52.2 million in the fourth quarter of 2006, while SG&A expenses increased 38.5 percent to $558 million from $403 million.
 
For full-year 2007, Thermo Fisher reported revenue of $9.75 billion, up from $3.79 billion for 2006. On a pro forma basis, revenues for 2006 would have been $8.87 billion and revenue growth for 2007 would have been 10 percent.
 
Net earnings for full-year 2007 were $761.1 million, or $1.72 per share, compared with $168.9 million, or $.84 per share, for 2006. The firm’s R&D spending rose to $238.7 million from $170.2 million in 2006, while SG&A costs rose sharply to $2.1 billion from $952.7 million.
 
Thermo Fisher finished 2007 with $636.2 million in cash and cash equivalents.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.